Sumitomo Pharma Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Sumitomo Pharma Bundle
Visual. Strategic. Downloadable.
Curious about Sumitomo Pharma's product portfolio performance? This snapshot offers a glimpse into their strategic positioning, but to truly understand their market dynamics, you need the full picture.
Uncover which of Sumitomo Pharma's products are driving growth, which are generating consistent revenue, and which require a strategic rethink. Purchase the complete BCG Matrix to gain actionable insights and a clear roadmap for optimizing their product strategy.
Stars
ORGOVYX (relugolix)
ORGOVYX, an oral androgen deprivation therapy for advanced prostate cancer, is a key growth engine for Sumitomo Pharma, especially in the North American market. Its robust sales trajectory and consistent revenue growth throughout fiscal year 2025 solidify its position as a Star in the BCG matrix. This reflects its significant market share within the expanding oncology sector.
The drug’s market expansion is further evidenced by its recent approval in Canada in March 2024. This strategic move broadens ORGOVYX's accessibility and potential for increased sales, reinforcing its status as a high-performing asset for Sumitomo Pharma.
GEMTESA (vibegron)
GEMTESA (vibegron) is a significant revenue driver for Sumitomo Pharma, particularly in North America, as a therapeutic agent for overactive bladder.
The product's sales forecast saw a substantial increase for FY2025, underscoring its strong market position and high share within a growing therapeutic segment.
This growth makes GEMTESA a cornerstone of Sumitomo Pharma's strategy for business recovery and expansion.
RETHYMIC (cultured thymus tissue)
RETHYMIC (cultured thymus tissue) is positioned as a Star in Sumitomo Pharma's BCG Matrix. This groundbreaking regenerative-tissue-based therapy for pediatric congenital athymia is the first of its kind globally, securing a dominant share in a niche but expanding medical market with significant unmet needs.
While sales are projected to remain stable for FY2025, RETHYMIC's high valuation and strategic role in regenerative medicine underscore its Star status, suggesting strong future growth prospects. The therapy tackles a serious condition associated with high healthcare expenditures, making it a crucial and valuable product for Sumitomo Pharma.
enzomenib (DSP-5336)
Enzomenib (DSP-5336), an investigational small molecule inhibitor for relapsed or refractory acute myeloid leukemia (AML), is positioned as a Star in Sumitomo Pharma's BCG Matrix. Its FDA Fast Track Designation in July 2024 highlights its significant potential in the growing oncology market.
Promising Phase 1/2 study data and the commencement of a pivotal study underscore its ability to address a critical unmet need in AML treatment. This progress indicates a strong likelihood of capturing substantial market share upon regulatory approval, reinforcing its Star status.
- Market Potential: Oncology drug market expected to reach $365.3 billion by 2027 (as of 2023 estimates).
- Regulatory Momentum: FDA Fast Track Designation in July 2024 signals expedited review and high market anticipation.
- Clinical Progress: Positive Phase 1/2 data and initiation of pivotal studies indicate strong efficacy and future market penetration.
- Competitive Landscape: Addresses a significant unmet need in relapsed/refractory AML, a segment with limited effective therapies.
nuvisertib (TP-3654)
Nuvisertib (TP-3654) is positioned as a potential star product for Sumitomo Pharma. Its role as an oral PIM1 kinase inhibitor targets myelofibrosis, a condition with significant unmet medical needs in the oncology market. The FDA's Fast Track Designation in June 2025 further highlights its promising development pathway and market potential.
Currently undergoing Phase 1/2 clinical trials, nuvisertib's expedited development is crucial for Sumitomo Pharma to capture market share in this high-growth sector. Strategic investment now is key to its successful transition into a substantial revenue-generating asset for the company.
- Product: Nuvisertib (TP-3654)
- Mechanism: Oral PIM1 kinase inhibitor
- Indication: Myelofibrosis
- Regulatory Status: FDA Fast Track Designation (June 2025)
- Development Stage: Phase 1/2 clinical trials
Stars: High-Growth Products Fueling Revenue
Sumitomo Pharma's Stars represent products with high market share in high-growth areas, driving significant revenue and future potential. These products are key to the company's current success and future expansion strategies.
ORGOVYX, GEMTESA, RETHYMIC, Enzomenib, and Nuvisertib are all classified as Stars due to their strong market positions, promising clinical development, and significant revenue generation or potential. Their performance underscores Sumitomo Pharma's strategic focus on key therapeutic areas with substantial growth prospects.
The oncology sector, where ORGOVYX, Enzomenib, and Nuvisertib operate, is projected for substantial growth, with market estimates reaching $365.3 billion by 2027. This robust market environment, coupled with the individual strengths of these products, solidifies their Star status.
| Product | Therapeutic Area | BCG Status | Key Growth Drivers | Market Data/Potential |
|---|---|---|---|---|
| ORGOVYX | Advanced Prostate Cancer | Star | Oral androgen deprivation therapy, strong sales, North American market expansion (approved in Canada March 2024) | Oncology market growth |
| GEMTESA | Overactive Bladder | Star | Significant revenue driver, increased sales forecast for FY2025, business recovery cornerstone | Growing therapeutic segment |
| RETHYMIC | Pediatric Congenital Athymia | Star | First-of-its-kind regenerative therapy, dominant niche market share, addresses high healthcare expenditure condition | Niche but expanding medical market |
| Enzomenib (DSP-5336) | Acute Myeloid Leukemia (AML) | Star | FDA Fast Track Designation (July 2024), promising Phase 1/2 data, pivotal study commencement | Oncology drug market ($365.3B by 2027), addresses unmet need in relapsed/refractory AML |
| Nuvisertib (TP-3654) | Myelofibrosis | Potential Star | FDA Fast Track Designation (June 2025), oral PIM1 kinase inhibitor, Phase 1/2 trials | High-growth oncology sector, addresses unmet medical needs |
What is included in the product
Detailed Word Document
Sumitomo Pharma's BCG Matrix offers a strategic overview, identifying which business units to invest in, hold, or divest based on market share and growth.
Customizable Excel Spreadsheet
Sumitomo Pharma's BCG Matrix offers a clear, visual roadmap, alleviating the pain of resource allocation uncertainty.
Cash Cows
LATUDA (Japan market)
LATUDA, known as lurasidone, continues to be a key product for Sumitomo Pharma in Japan, despite its loss of exclusivity in the US in 2023. In its mature Japanese market, LATUDA likely holds a strong, stable market share, acting as a reliable source of cash flow for the company.
Sumitomo Pharma actively supports LATUDA's performance in Japan by focusing on providing essential medical information to healthcare professionals. This strategic approach ensures the product's continued relevance and contribution to the company's revenue stream in this specific market.
LONASEN Tape
LONASEN Tape, an established atypical antipsychotic, continues to be a stable revenue generator for Sumitomo Pharma in Japan's mature psychiatry and neurology market. Its consistent performance allows for minimal promotional and placement investments, solidifying its position as a reliable cash cow. In 2024, Sumitomo Pharma reported that its neuroscience segment, which includes LONASEN, contributed significantly to overall sales, demonstrating the product's enduring market presence.
XEPLION / XEPLION TRI
XEPLION and XEPLION TRI, long-acting antipsychotic medications, are positioned as Cash Cows within Sumitomo Pharma's BCG Matrix. Co-promoted with Janssen Pharmaceutical K.K. since February 2025, these products operate in a mature but vital market segment, signifying a strategy focused on optimizing cash flow from established offerings.
This co-promotion approach allows Sumitomo Pharma to leverage existing market presence and distribution networks, ensuring consistent revenue generation. The reliable returns from these medications require only moderate investment for maintenance and marketing, reinforcing their Cash Cow status.
TWYMEEG
TWYMEEG, a therapeutic agent for type 2 diabetes, functions within a substantial and well-established market. This positioning suggests it commands a solid market share, contributing significantly to Sumitomo Pharma's revenue streams.
The company's efforts to enhance TWYMEEG's sales, alongside its other diabetes treatments, indicate its role as a reliable cash generator. This strategy implies that TWYMEEG requires minimal new investment for growth, allowing it to provide consistent financial returns.
- Market Position: TWYMEEG operates in the large, mature type 2 diabetes market.
- Cash Flow Generation: It serves as a consistent cash flow contributor for Sumitomo Pharma.
- Investment Strategy: Sales bolstering efforts suggest it's a mature product, not requiring heavy growth investment.
- Revenue Contribution: TWYMEEG forms a foundational element of the company's overall revenue.
MEROPEN (prior to JV transfer)
Meropen, a carbapenem antibiotic, historically represented a significant cash cow for Sumitomo Pharma, particularly within its Asia and China operations. This drug held a strong market position in a mature therapeutic segment, consistently generating substantial revenue.
While the specific financial figures for Meropen prior to the joint venture transfer are not publicly detailed, its classification as a cash cow implies robust and stable sales. In 2024, the broader antibiotic market, while facing challenges like antimicrobial resistance, continued to be a vital healthcare segment. Sumitomo Pharma's strategic decision to transfer this business to a joint venture suggests a move to optimize its portfolio, but Meropen's historical role as a stable income stream is undeniable.
- Product: Meropen (Carbapenem Antibiotic)
- Historical Role: Stable Cash Generator
- Market Position: High Market Share in Mature Therapeutic Area (Asia & China)
- Strategic Context: Prior to Joint Venture Transfer
Sumitomo Pharma's Cash Cows: Stable Revenue Generators
LATUDA, LONASEN Tape, XEPLION, XEPLION TRI, TWYMEEG, and Meropen are all identified as Cash Cows for Sumitomo Pharma. These products operate in mature markets, generating consistent revenue with minimal need for significant new investment. Their stable performance contributes reliably to the company's overall financial health.
| Product | Therapeutic Area | Market Status | BCG Category | Key Contribution |
| LATUDA | Antipsychotic | Mature (Japan) | Cash Cow | Stable Revenue |
| LONASEN Tape | Antipsychotic | Mature (Japan) | Cash Cow | Consistent Cash Flow |
| XEPLION / XEPLION TRI | Antipsychotic | Mature | Cash Cow | Optimized Cash Flow |
| TWYMEEG | Type 2 Diabetes | Mature | Cash Cow | Foundational Revenue |
| Meropen | Antibiotic | Mature (Asia & China) | Cash Cow (Historical) | Substantial Revenue |
Delivered as Shown
Sumitomo Pharma BCG Matrix
The Sumitomo Pharma BCG Matrix preview you see is the complete, unadulterated document you will receive immediately after purchase. This means no watermarks, no demo content, and no missing sections – just the fully formatted, professionally analyzed matrix ready for your strategic decision-making.
Rest assured, the Sumitomo Pharma BCG Matrix you are currently viewing is precisely the same high-quality report you will download once your purchase is complete. It’s been meticulously prepared with expert analysis, ensuring you receive an actionable tool for evaluating Sumitomo Pharma's product portfolio without any surprises or need for further editing.
What you are previewing is the actual, final Sumitomo Pharma BCG Matrix file that will be delivered to you upon purchase. This allows you to confirm its comprehensive nature and professional presentation before committing, guaranteeing you receive an immediately usable and insightful strategic document.
Dogs
APTIOM (eslicarbazepine acetate)
APTIOM, known chemically as eslicarbazepine acetate, is positioned as a 'Dog' within Sumitomo Pharma's BCG Matrix. This classification stems from its anticipated significant sales decline following the loss of exclusivity in May 2025. The forecast for fiscal year 2025 reflects a substantial drop in revenue due to this event.
Products like APTIOM, upon losing patent protection, are highly susceptible to rapid market share erosion and profitability reduction from generic competitors. This competitive pressure directly impacts its ability to generate substantial net cash flow, a key indicator for its 'Dog' status.
Consequently, the strategic approach for APTIOM involves minimizing further investment. The focus shifts to managing its decline rather than pursuing growth initiatives, aligning with the typical strategy for products in the 'Dog' quadrant of the BCG Matrix.
TRERIEF (zonisamide)
TRERIEF (zonisamide), a Parkinson's disease therapeutic agent, entered a low-growth phase in Japan following the expiration of its exclusivity period in June 2024. This transition signifies a shift towards a low-market-share category due to the introduction of generic alternatives.
Given the patent expiry and the subsequent market dynamics, TRERIEF is positioned as a potential 'Dog' within Sumitomo Pharma's BCG Matrix. Continued investment in this product is unlikely to generate significant returns, suggesting a strategic review for divestiture or a reduction in operational support.
Equa / EquMet
Equa and EquMet, once key players in type 2 diabetes treatment, now face significant challenges. Equa's patent exclusivity ended in December 2024, pushing it into a crowded, mature market where its market share is shrinking. This loss of exclusivity directly impacts profitability.
As a result, these products are poised to become cash traps. They will likely consume resources without generating substantial returns, forcing Sumitomo Pharma to carefully consider their future within the company's broader portfolio strategy.
vibegron (China development)
Vibegron, known as GEMTESA in other regions, faces a challenging situation in China. Despite its success elsewhere, its development strategy for the Chinese market is currently being re-evaluated.
This re-evaluation follows an unsuccessful bridging study aimed at treating overactive bladder. This outcome suggests a limited market share and low growth potential for vibegron within China.
- Low Market Share in China: Vibegron's bridging study failure indicates a weak initial foothold in the Chinese overactive bladder market.
- Low Growth Prospects: The unsuccessful study directly impacts future market growth expectations for vibegron in China.
- Strategic Re-evaluation: Sumitomo Pharma is reconsidering its investment and development approach for vibegron in China due to these challenges.
- Inefficient Investment: Continuing to invest heavily without a clear path to market adoption would represent an inefficient use of resources.
Older, Non-Strategic Legacy Products
Sumitomo Pharma, a company with a deep history in pharmaceuticals, likely possesses a collection of older medications. These drugs, often found in well-established treatment areas, are probably experiencing a downturn in sales and hold a small portion of their respective markets. Such products, not identified as primary growth engines, would be classified as Dogs within the BCG matrix.
These legacy products typically operate at a break-even point or might even require cash for ongoing maintenance. Their contribution to Sumitomo Pharma's overall expansion is minimal, making them less of a strategic focus. For instance, a drug that once dominated a therapeutic area might now face intense competition from newer, more effective treatments, leading to its decline.
- Declining Sales: Older products often see a gradual decrease in revenue as newer alternatives emerge.
- Low Market Share: In mature markets, these drugs typically hold a small percentage of the total market.
- High Maintenance Costs: Despite low sales, ongoing costs for regulatory compliance and production can persist.
- Cash Consumption: These products may require investment without generating significant returns, thus consuming cash.
Pharma's "Dogs": Declining Sales & Strategic Shifts
APTIOM's classification as a 'Dog' is reinforced by its projected significant sales decline post-May 2025 exclusivity loss. This decline is typical for drugs facing generic competition, which erodes market share and profitability. Consequently, APTIOM is unlikely to generate substantial net cash flow, leading to a strategic focus on managing its decline rather than investing in growth.
TRERIEF, following its June 2024 exclusivity expiration in Japan, has entered a low-growth phase with a reduced market share due to generic alternatives. This positions it as a potential 'Dog,' where continued investment is unlikely to yield significant returns, suggesting a potential divestiture or reduced operational support.
Equa and EquMet, with Equa's patent expiry in December 2024, are now in mature, competitive markets with shrinking market share. These products are likely to become cash traps, consuming resources without substantial returns, necessitating careful portfolio management by Sumitomo Pharma.
Vibegron's unsuccessful bridging study in China for overactive bladder suggests limited market share and low growth potential. This outcome is prompting a strategic re-evaluation of its development in China, as continued investment without market adoption would be inefficient.
| Product | Therapeutic Area | BCG Status | Key Factors |
|---|---|---|---|
| APTIOM | Epilepsy | Dog | Loss of Exclusivity (May 2025), Declining Sales, Generic Competition |
| TRERIEF | Parkinson's Disease | Dog (Potential) | Exclusivity Expiration (June 2024), Low Growth Phase, Generic Entry |
| Equa | Type 2 Diabetes | Dog (Potential) | Patent Expiry (Dec 2024), Mature Market, Shrinking Market Share |
| EquMet | Type 2 Diabetes | Dog (Potential) | Mature Market, Shrinking Market Share, Potential Cash Trap |
| Vibegron (China) | Overactive Bladder | Dog (Potential) | Unsuccessful Bridging Study, Limited Market Share, Low Growth Prospects |
Question Marks
CT1-DAP001/DSP-1083 (Parkinson's iPS cell therapy)
CT1-DAP001/DSP-1083, Sumitomo Pharma's allogeneic iPS cell-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, is positioned as a potential Star in the BCG matrix. This therapy is gearing up for an NDA submission in Japan around August 2025 and is entering Phase 1/2 trials in the US, signaling its entry into the rapidly expanding regenerative medicine market.
While the market for Parkinson's treatments is substantial and growing, CT1-DAP001/DSP-1083 currently holds a negligible market share. The significant investment required for its development, coupled with its potential to disrupt the Parkinson's treatment landscape, underscores its high-growth, high-risk profile.
The strategic partnership for its development further emphasizes its importance to Sumitomo Pharma's pipeline. Success in these upcoming regulatory and clinical stages could propel this therapy into a leading market position, justifying its current classification as a potential Star with substantial future upside.
HLCR011 (Retinal iPS cell therapy)
HLCR011, Sumitomo Pharma's allogeneic iPS cell-derived retinal pigment epithelial cell therapy for retinal pigment epithelium tear, is currently in Phase 1/2 studies in Japan. This innovative treatment targets a significant unmet need within the burgeoning regenerative medicine sector.
Positioned as a potential star in the BCG matrix, HLCR011 operates in a high-growth market with substantial future potential. However, it currently holds no market share, reflecting its early-stage development. The global regenerative medicine market was valued at approximately USD 14.4 billion in 2023 and is projected to grow at a CAGR of over 25% through 2030, indicating the immense opportunity.
The significant capital investment necessary for clinical trials and market penetration places HLCR011 in a high-risk, high-reward category. Sumitomo Pharma's commitment to advancing this therapy underscores its strategic focus on pioneering treatments, even with the inherent uncertainties of early-stage biotechnology.
Universal Influenza Vaccine
Sumitomo Pharma's universal influenza vaccine candidate is currently in a Phase I clinical trial in Europe, with interim results anticipated by the close of 2025. This positions the product as a potential future contender in a lucrative vaccine market, though it currently holds no market share due to its early development stage.
The development of a universal influenza vaccine represents a significant opportunity, given the global demand for more effective and broadly protective influenza immunizations. However, the substantial research and development costs associated with proving efficacy and achieving widespread market adoption mean this product requires considerable ongoing investment.
DSP-0038 (Alzheimer's disease psychosis)
DSP-0038, a small molecule targeting psychosis in Alzheimer's disease, is currently in Phase 1 trials in the United States. This positions it as a potential future entrant in a market characterized by substantial unmet medical needs and significant growth prospects.
The Alzheimer's treatment market is projected to reach $16.1 billion by 2027, highlighting its immense potential. However, DSP-0038's early-stage development means it currently holds no market share and faces considerable investment requirements and inherent risks associated with clinical trials.
- Product: DSP-0038 (Alzheimer's disease psychosis)
- Development Stage: Phase 1 in the US
- Market Potential: High growth, significant unmet need in Alzheimer's treatments
- BCG Matrix Classification: Question Mark (due to early stage and high investment needs)
DSP-3456 (Treatment resistant depression)
DSP-3456, currently in Phase 1 trials in the United States, is Sumitomo Pharma's candidate for treatment-resistant depression (TRD). This condition represents a significant unmet medical need, with the TRD market projected for substantial growth. In 2024, the global depression market was valued at approximately $5.7 billion, with TRD accounting for a notable segment.
As an early-stage asset, DSP-3456 has no current market share and requires considerable research and development investment to prove its efficacy and safety. The success of its clinical trials is crucial for its future positioning.
If DSP-3456 successfully navigates its clinical development and gains regulatory approval, it has the potential to become a Star product for Sumitomo Pharma in the BCG matrix. This would signify high market growth and the potential for significant future revenue, especially given the limited effective treatment options currently available for TRD patients.
- Product: DSP-3456 (Treatment-resistant depression)
- Stage: Phase 1 in the US
- Market Potential: High unmet need, growing market
- BCG Classification Potential: Star (if successful)
Pharma's Pipeline: Early Stage, High Potential
DSP-0038, targeting psychosis in Alzheimer's disease, is in Phase 1 trials in the US. This positions it as a potential future entrant in a market with significant unmet needs and growth prospects, projected to reach $16.1 billion by 2027. Its early stage means no current market share and substantial investment needs, classifying it as a Question Mark.
DSP-3456, for treatment-resistant depression, is also in Phase 1 trials in the US. The depression market was valued at approximately $5.7 billion in 2024, with TRD being a notable segment. Currently a Question Mark, its success in clinical trials could elevate it to a Star product.
Sumitomo Pharma's universal influenza vaccine candidate is in Phase I trials in Europe, with interim results expected by late 2025. This product is a Question Mark due to its early stage and no current market share, but it aims for a lucrative vaccine market.
| Product | Indication | Stage | Market | BCG Classification |
|---|---|---|---|---|
| DSP-0038 | Alzheimer's disease psychosis | Phase 1 (US) | High growth, $16.1B by 2027 | Question Mark |
| DSP-3456 | Treatment-resistant depression | Phase 1 (US) | Growing, $5.7B (depression) in 2024 | Question Mark (potential Star) |
| Universal Influenza Vaccine | Influenza | Phase 1 (Europe) | Lucrative vaccine market | Question Mark |